News | March 24, 2008

Data on Percutaneous Valve Repair Presented at SCAI-ACCi2

March 25, 2008 - Data on the MitraClip, a device that just received CE Mark approval and is designed to nonsurgically treat the effects of mitral regurgitation (ischemic and cardiomyopathy), will be presented at the SCAI-ACCi2 annual meeting in Chicago as part of the late-breaking clinical trial program on Tuesday, April 1.

James Hermiller, M.D., director of the interventional fellowship program at St. Vincent Heart Center of Indiana in Indianapolis, IN, will make the presentation.

Evalve Inc., the manufacturer of the MitraClip system, recently completed enrollment in the high-risk registry arm of the Endovascular Valve Edge-to-Edge REpair STudy (EVEREST) in North America. Patients who are high-risk surgical candidates may benefit from a less invasive procedure. Investigators are collecting follow-up data to assess the risk-benefit profile from the less invasive percutaneous intervention with the MitraClip device.

The EVEREST investigators from more than 40 sites across North America have treated more than 300 patients with close to 400 MitraClip devices implanted. Trial data continues to grow with three-year follow up results available as well as four-year data from some patients.

For more information: www.scai-acci2.org and www.evalveinc.com

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init